<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03002896</url>
  </required_header>
  <id_info>
    <org_study_id>16-0990</org_study_id>
    <nct_id>NCT03002896</nct_id>
  </id_info>
  <brief_title>Mobilized Psychoeducation and Skills Based Intervention (Pep-Pal) for Caregivers of Patients With Advanced Illness</brief_title>
  <official_title>A Randomized Controlled Trial of Mobilized Psychoeducation and Skills Based Intervention (Pep-Pal) for Caregivers of Patients With Advanced Illness</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed project is a pilot randomized control trial of the Pep-Pal (Psychoeducation and
      Skills Based Intervention) versus a treatment as usual control group. A total of 120
      caregivers; 40 caregivers of patients with HSCT (Hematopoietic Stem Cell Transplantation), 40
      caregivers of patients enrolled in phase I oncology trials, and 40 caregivers of patients
      with advanced cancer (Stage IV, solid tumor) will be enrolled in this study. The
      investigators do not expect different outcomes from these three groups, rather these
      populations are selected to optimize recruitment within a short time frame. The caregivers
      will be randomized to either treatment as usual or Pep-Pal intervention.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed project is a pilot randomized control trial of the Pep-Pal intervention versus a
      treatment as usual control group. A total of 120 caregivers; 40 caregivers of patients with
      HSCT, 40 caregivers of patients enrolled in phase I oncology trials, and 40 caregivers of
      patients with advanced cancer (Stage IV, solid tumor) will be enrolled in this study. The
      investigators do not expect different outcomes from these three groups, rather these
      populations are selected to optimize recruitment within a short time frame. The caregivers
      will be randomized to either treatment as usual or Pep-Pal intervention. The proposed study
      population is based on prior research indicating that caregivers of patients receiving HSCT,
      caregivers of patients enrolled in phase I oncology trials, and caregivers of patients with
      advanced cancer experience significant distress. In addition, an initial study of caregivers
      of patients receiving allogeneic-HSCT were able to benefit from a brief, cognitive behavioral
      stress management treatment approach. A study examining distress in phase I oncology clinical
      trial patient caregivers highlighted the need for more support for this significantly
      distressed population. Furthermore, initial results of the qualitative development study for
      Pep-Pal yielded support for a mobilized platform delivery of resources for caregivers to
      manage distress because they acknowledged many barriers to engaging in in-person treatment to
      manage distress.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2016</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of Exit Interviews</measure>
    <time_frame>12 weeks</time_frame>
    <description>Qualitative feedback will be gathered from the first 15 Pep-Pal completer's for individual interviews (5 from Phase I group, 5 from Hematopoietic stem cell transplantation (HSCT) group, 5 from medical oncology) upon completion of the follow-up assessments at 12 weeks about usage, acceptability of content, and impressions of using Pep-Pal.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pep-Pal Self-Report sessions at 12 Weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>The Investigators will assess feasibility by examining recruitment, retention, as well as reasons for refusal, frequency of sessions watched and length of time spent watching each session. Self report usage of peppal: Usage of Pep-Pal will be quantitatively assessed by asking each participant in the intervention group about their usage including frequency; how many times they watched each session and length of viewing for each session (partial or complete). They will be asked to rate level of usage based on a Likert-scale ranging from not at all to very often for each session (0-10). They will be asked to rank order the list of sessions from most helpful to least helpful.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of Self-Report Caregiver reported outcomes at Baseline</measure>
    <time_frame>Week 1</time_frame>
    <description>Hospital Anxiety and Depression Scale-Anxiety subscale (HADS-A)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of Self-Report Caregiver reported outcomes at Baseline</measure>
    <time_frame>Week 1</time_frame>
    <description>Center for Epidemiologic Studies Depression Scale (CESD)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of Self-Report Caregiver reported outcomes at Baseline</measure>
    <time_frame>Week 1</time_frame>
    <description>Perceived Stress Scale (PSS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of Self-Report Caregiver reported outcomes at Baseline</measure>
    <time_frame>Week 1</time_frame>
    <description>Female Sexual Function Index (FSFI)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of Self-Report Caregiver reported outcomes at Baseline</measure>
    <time_frame>Week 1</time_frame>
    <description>Patient-Reported Outcomes Measurement Information System (PROMIS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of Self-Report Caregiver reported outcomes at Baseline</measure>
    <time_frame>Week 1</time_frame>
    <description>Male Sexual Health Questionnaire(MSHQ)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of Self-Report Caregiver reported outcomes at Baseline</measure>
    <time_frame>Week 1</time_frame>
    <description>Measure of Current Status (MOCS-A)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of Self-report caregiver reported outcomes at 12 weeks</measure>
    <time_frame>Week 12</time_frame>
    <description>Center for Epidemiologic Studies Depression Scale (CESD)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of Self-report caregiver reported outcomes at 12 weeks</measure>
    <time_frame>Week 12</time_frame>
    <description>Perceived Stress Scale (PSS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of Self-report caregiver reported outcomes at 12 weeks</measure>
    <time_frame>Week 12</time_frame>
    <description>Female Sexual Function Index (FSFI)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of Self-report caregiver reported outcomes at 12 weeks</measure>
    <time_frame>Week 12</time_frame>
    <description>Patient-Reported Outcomes Measurement Information System (PROMIS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of Self-report caregiver reported outcomes at 12 weeks</measure>
    <time_frame>Week 12</time_frame>
    <description>Male Sexual Health Questionnaire(MSHQ),</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of Self-report caregiver reported outcomes at 12 weeks</measure>
    <time_frame>Week 12</time_frame>
    <description>Measure of Current Status (MOCS-A)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of Self-report caregiver reported outcomes at 12 weeks</measure>
    <time_frame>Week 12</time_frame>
    <description>Hospital Anxiety and Depression Scale-Anxiety subscale (HADS-A)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Distress</condition>
  <condition>Anxiety</condition>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Pep-Pal + Treatment as Usual</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>If the caregiver is assigned to the Pep-Pal intervention condition, the RA will provide access to the mobilized website (passcode) through an email. Caregivers will be instructed to watch each session at least once. It will be recommended that caregivers watch one to two new sessions per week so that they can have enough time to practice the skills between sessions. In addition, they will be told that they can go back and watch the sessions for review as many times as they like. Full participation will be defined as watching at least 7/9 sessions (75% of program) based on previous criteria for similar intervention completion in a prior trial with advanced cancer patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment as Usual</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment as usual provides voluntary (at the caregiver's discretion) support services for the caregivers which is rarely used by the caregivers.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Pep-Pal</intervention_name>
    <description>Pep-Pal is designed to complement the utilization of other resources, provide support when no other resources can be obtained, or provide support in the interim until greater resources can be obtained. In this way, Pep-Pal is a resource for our most hard to reach caregivers.</description>
    <arm_group_label>Pep-Pal + Treatment as Usual</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Treatment as Usual</intervention_name>
    <arm_group_label>Pep-Pal + Treatment as Usual</arm_group_label>
    <arm_group_label>Treatment as Usual</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Women and men â‰¥ 18 years of age of any ethnicity

          2. Must endorse a moderate level of anxiety (e.g. Score above an 8 on the Hospital and
             Anxiety Depression Scale (HADS))

          3. Speak and read in English

          4. Caregiver of a patient with auto HSCT who are moving forward with bone marrow
             transplant or have receive a bone marrow transplant

          5. Caregiver of a patient in a Phase I Clinical Trial

          6. Caregiver of a patient diagnosed with advanced cancer (stage III or stage IV)

          7. No Cognitive or psychiatric conditions prohibiting participation

          8. Must meet criteria for being a primary caregiver, defined as, the person in the
             patient's life who is primarily responsible for care decisions, emotionally invested
             in the patient's care, provides instrumental care such as transportation for a patient
             receiving auto-HSCT, enrolled in a phase I oncology clinical trial, or of a patient
             diagnosed with advanced cancer (stage IV, solid tumor).

          9. Have a computer, smartphone, or tablet with internet access

        Exclusion Criteria:

          1. Caregivers below the age of 18

          2. Score below an 8 on the Hospital and Anxiety Depression Scale (HADS)

          3. Cannot speak and read in English

          4. Patient does not receive a bone marrow transplant

          5. Patient is not enrolled in a Phase I clinical trial

          6. Patient is not diagnosed with Stage III or Stage IV cancer

          7. Cognitive conditions prohibiting participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicole R Amoyal-Pensak, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alaina L Carr, BA</last_name>
    <phone>301-452-7079</phone>
    <email>alaina.carr@ucdenver.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Colorado, Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alaina L Carr, BA</last_name>
      <phone>301-452-7079</phone>
      <email>alaina.carr@ucdenver.edu</email>
    </contact>
    <investigator>
      <last_name>Nicole R Amoyal-Pensak, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 28, 2016</study_first_submitted>
  <study_first_submitted_qc>December 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 26, 2016</study_first_posted>
  <last_update_submitted>August 29, 2017</last_update_submitted>
  <last_update_submitted_qc>August 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>Caregivers</keyword>
  <keyword>Pep-pal</keyword>
  <keyword>Pep-Pal + Treatment as Usual</keyword>
  <keyword>Treatment as Usual</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

